CRIS
What one share of Curis holds
Biological Products, (No Diagnostic Substances)
We are a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase, or IRAK4 and FMS-like tyrosine kinase 3 or FLT3.
Curis’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $3.68 |
|---|---|
| Profit | −$18.06 |
| Cash and investments | $2.60 |
| Book value | $2.41 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $113.37 | −$909.90 | $4.96 | −$544.34 | — | $417.38 |
| 2017 | $132.74 | −$715.02 | $2.52 | −$651.00 | — | $292.32 |
| 2018 | $125.95 | −$393.44 | $1.03 | −$364.15 | — | −$54.24 |
| 2019 | $120.60 | −$387.47 | $0.49 | −$316.40 | — | −$408.05 |
| 2020 | $89.05 | −$245.80 | $5.56 | −$217.10 | — | $571.22 |
| 2022 | $43.52 | −$242.73 | $1.78 | −$234.51 | — | $192.74 |
| 2023 | $37.87 | −$179.14 | $0.00 | −$145.22 | — | $66.74 |
| 2024 | $34.59 | −$137.61 | — | −$125.47 | — | −$14.13 |
| 2025 | $14.35 | −$11.52 | — | −$41.33 | — | $8.45 |